Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc.
Company type	Public
Traded as	Nasdaq: ANTH
Industry	Pharmaceuticals
Founded	2004
Headquarters	Hayward, California, U.S.
Key people	Craig Thompson; (President and CEO)
Website	Anthera.com

Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy^[1]^[2] is currently in Phase 2 clinical trial.

Products

Blisibimod

Blisibimod is a selective peptibody antagonist of B-cell activating factor (BAFF). BAFF is critical to the development, maintenance and survival of B-cells, but is known to be up-regulated in autoimmune diseases.^[3]^[4]^[5] It is primarily expressed by macrophages, monocytes and dendritic cells.^[6] Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors.^[7] Blisibimod is currently being evaluated in IgA nephropathy.

Sollpura

In July 2014, Anthera acquired Sollpura (Liprotamase) from Eli Lilly and Company.^[8] Sollpura is an investigational pancreatic enzyme replacement therapy (PERT) that uses three biotechnology-derived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases.^[9]

References

^ "Overview". Anthera Pharmaceuticals, Inc. Archived from the original on August 21, 2014. Retrieved August 11, 2014.
^ "Management Team". Anthera Pharmaceuticals, Inc. Archived from the original on August 12, 2014. Retrieved August 11, 2014.
^ Groom, J; Kalled, SL; Cutler, AH; Olson, C; Woodcock, SA; Schneider, P; Tschopp, J; Cachero, TG; Batten, M; Wheway, J; Mauri, D; Cavill, D; Gordon, TP; Mackay, CR; Mackay, F (Jan 2002). "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome". J Clin Invest. 109 (1): 59–68. doi:10.1172/JCI14121. PMC 150825. PMID 11781351.
^ Petri, Michelle; Stohl, William; Chatham, Winn; McCune, Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William (2008). "ARTHRITIS & RHEUMATISM Vol. 58, No. 8, August 2008, pp 2453–2459 DOI 10.1002/art.23678 © 2008, American College of Rheumatology Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus" (PDF). Arthritis and Rheumatism. 58 (8). American College of Rheumatology: 2453–2459. doi:10.1002/art.23678. hdl:2027.42/60900. PMID 18668552. Retrieved August 11, 2014.
^ Zhang, J; Roschke, K; Baker, KP; Wang, Z; Alarcon, GS; Fessler, BJ; Bastian, H; Kimberly, RP; Zhou, T (2001). "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus". Journal of Immunology. 166 (1). J Immunol: 6–10. doi:10.4049/jimmunol.166.1.6. PMID 11123269.
^ "Product Candidates". Anthera Pharmaceuticals, Inc. Archived from the original on August 16, 2014. Retrieved August 11, 2014.
^ Hsu, H; Khare, SD; Lee, F; Miner, K; Hu, YL; Stolina, M; Hawkins, N; Chen, Q; Ho, SY; Min, H; Xiong, F; Boone, T; Zack, DJ. "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease". Clin Exp Rheumatol. 30 (2). Clinical and Experimentla Rheumatology: 197–201. PMID 22325420.
^ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Archived from the original on August 12, 2014. Retrieved August 11, 2014.
^ "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Archived from the original on August 12, 2014. Retrieved August 11, 2014. Sollpura narrowly missed its target for Phase 3 of its clinical trials. It believes that specific conditions in the testing phase, specifically that patients were not able to increase dosages throughout the trial, negatively affected testing and led to the narrow shortcoming for Phase 3. It will conduct a new trial compensating for the perceived shortcoming at some point in the future.

External links

Official website

[1] "Overview". Anthera Pharmaceuticals, Inc. Archived from the original on August 21, 2014. Retrieved August 11, 2014.

[2] "Management Team". Anthera Pharmaceuticals, Inc. Archived from the original on August 12, 2014. Retrieved August 11, 2014.

[3] Groom, J; Kalled, SL; Cutler, AH; Olson, C; Woodcock, SA; Schneider, P; Tschopp, J; Cachero, TG; Batten, M; Wheway, J; Mauri, D; Cavill, D; Gordon, TP; Mackay, CR; Mackay, F (Jan 2002). "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome". J Clin Invest. 109 (1): 59–68. doi:10.1172/JCI14121. PMC 150825. PMID 11781351.

[4] Petri, Michelle; Stohl, William; Chatham, Winn; McCune, Joseph; Chevrier, Marc; Ryel, Jeff; Recta, Virginia; Zhong, John; Freimuth, William (2008). "ARTHRITIS & RHEUMATISM Vol. 58, No. 8, August 2008, pp 2453–2459 DOI 10.1002/art.23678 © 2008, American College of Rheumatology Association of Plasma B Lymphocyte Stimulator Levels and Disease Activity in Systemic Lupus Erythematosus" (PDF). Arthritis and Rheumatism. 58 (8). American College of Rheumatology: 2453–2459. doi:10.1002/art.23678. hdl:2027.42/60900. PMID 18668552. Retrieved August 11, 2014.

[5] Zhang, J; Roschke, K; Baker, KP; Wang, Z; Alarcon, GS; Fessler, BJ; Bastian, H; Kimberly, RP; Zhou, T (2001). "Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus". Journal of Immunology. 166 (1). J Immunol: 6–10. doi:10.4049/jimmunol.166.1.6. PMID 11123269.

[6] "Product Candidates". Anthera Pharmaceuticals, Inc. Archived from the original on August 16, 2014. Retrieved August 11, 2014.

[7] Hsu, H; Khare, SD; Lee, F; Miner, K; Hu, YL; Stolina, M; Hawkins, N; Chen, Q; Ho, SY; Min, H; Xiong, F; Boone, T; Zack, DJ. "A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease". Clin Exp Rheumatol. 30 (2). Clinical and Experimentla Rheumatology: 197–201. PMID 22325420.

[8] "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Archived from the original on August 12, 2014. Retrieved August 11, 2014.

[9] "Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company". Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals. Archived from the original on August 12, 2014. Retrieved August 11, 2014. Sollpura narrowly missed its target for Phase 3 of its clinical trials. It believes that specific conditions in the testing phase, specifically that patients were not able to increase dosages throughout the trial, negatively affected testing and led to the narrow shortcoming for Phase 3. It will conduct a new trial compensating for the perceived shortcoming at some point in the future.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]